Maxim – Positive Survival Data for Efti Triple Combo in 1L NSCLC; Bodes Well for Upcoming P3 Pivotal TACTI-004 Study in Same Setting – Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)